

For Regions and Systems

- The decision to allow selected Vaccination Centres and community pharmacy LVS sites to extend their vaccination offer to people who are immunosuppressed will be made by the Senior Responsible Officer (SRO)/Regional Director of Commissioning (RDC) after a recommendation from the Vaccination Lead within the Integrated Care System (ICS)/STP. This selection should be made after consideration of the population need, available system capacity and all available sites who would be best placed to meet that need. This decision needs to be documented.
- **Regional Directors of Commissioning** together with local System vaccination leads should identify where additional vaccination offers through Vaccination Centres (for individuals 12-15 and where they are able to comply with the [self-assessment checklist Part A and B](#)) and Vaccination Centres and community pharmacy LVS sites (for individuals 16 and over and where they are able to comply with the [self-assessment checklist Part A](#)) are required for providing a third primary dose for eligible severely immunosuppressed individuals identified via their GP or secondary care and engage these providers in this offer. These patients must be offered vaccinations within the interval advised by their specialist consultant or GP, with support from the specialist consultant where appropriate.
- Regions with local CCGs must agree a process and governance mechanism of how people who are immunosuppressed are identified by their GP practice and hospital consultant and offered a vaccination appointment. The decision to allow selected Vaccination Centres (for individuals 12 and over) and community pharmacy LVS sites (for individuals 16 and over) to extend their vaccination offer to people who are immunosuppressed should sit with the Senior Responsible Officer (SRO)/Regional Director of Commissioning (RDC) after a recommendation from the Vaccination Lead within the Integrated Care System (ICS)/STP.

Recording of the third primary dose vaccination event:

The third dose should be recorded as a booster dose in the point of care system. Records will be retrospectively amended through a national process to ensure that the third primary dose is accurately recorded as such. This will ensure distinction is made between a third primary dose and a booster dose and that individuals are invited for any subsequent doses should that be recommended.

For HH and HH+ leads

HH+ and HH sites may use local booking systems to invite individuals and may also accept walk-ins. Individuals who walk in will need to provide a clinical letter to confirm their eligibility and the timing of their 3rd dose. Eligible individuals will not be able to book a third dose via the National Booking Service.

- **For the vaccination of severely immunosuppressed individuals aged 12 to 15**, HH+ must have regional approval and comply with the same

requirements of vaccinating 12 to 15 year old children who are clinically extremely vulnerable or household contacts (compliant with the criteria in the self-assessment checklists [Part A](#) and [Part B](#))

For Vaccination Centres and community pharmacy LVS sites Leads

Individuals will not be able to book a third dose via the National Booking Service (NBS). A small number of individuals may walk in and will need to provide a clinical letter to confirm their eligibility and the timing of their 3rd dose. Where gaps in vaccination offer coverage have been identified by System and Regional leads, regionally approved sites may invite eligible severely immunosuppressed patients to book at VCs and community pharmacy LVS sites via their local booking system, or provide targeted communications to this cohort with information on vaccination sites offering walk-ins.

- **For the vaccination of severely immunosuppressed individuals aged 12 to 15**, VCs must have been approved through their regional leads to comply with the same requirements of vaccinating 12 to 15 year old children who are clinically extremely vulnerable or household contacts (compliant with the criteria in the self-assessment checklists [Part A](#) and [Part B](#)). Community pharmacy LVS sites must not offer vaccinations to any patient aged 12 to 15 year old.
- **For the vaccination of severely immunosuppressed individuals aged 16 and 17**, VCs and community pharmacy LVS sites must have been approved through their regional leads to comply with the requirements set out in the [workforce consideration document](#) and the [self-assessment checklist Part A](#). Further guidance has been provided in our [operational note from 4 August](#) and for [Vaccination Centres in this SOP](#).

All sites have to adhere to the [infection control guidance](#). This indicates the measures that need to be undertaken if a pathway is considered high or medium risk. All sites are to operate under the PGD that has been updated and published on 21 September: [COVID-19 vaccination programme - GOV.UK \(www.gov.uk\)](#)